Recent research led by the University of Exeter and King’s College London, which has still to be published compared pre-pandemic care home prescribing rates for antipsychotic drugs to treat severe dementia in 2016-17 with those in 2021-2.
The pre-COVID-19 data included 971 residents from 69 care homes, and the post-COVID-19 figures involved 747 individuals across 149 care homes taken from baseline data of the “Improving the Wellbeing and Health for People Living with Dementia” (iWHELD) study. Both study participant groups had an average age of about 85 and a similar gender balance of approximately 70% women and 30% men. There were fewer people with severe dementia in the iWHELD cohort compared with the earlier study (6.7% v 23%).
Analysis found that antipsychotic usage was 55% higher post-COVID when compared with pre-COVID (28% v 18%), despite similar rates of neuropsychiatric symptoms. 64% of participating care homes had experienced an outbreak of COVID.
To ensure that the results were not confounded by the lower number of people with severe dementia in the most recent study, the researchers widened the scope to include residents with ‘moderate’ and ‘moderately severe’ dementia. However, the results remained very similar.
Any study that identifies a substantial rise in antipsychotics given to people with dementia in UK is shocking, because of the risk of serious side effects, such as stroke, accelerated decline, and mortality from these medicines that has been known about since the findings of Professor Sube Banerjee’s (2009) Report entitled “The use of antipsychotic medication for people with dementia”. This report highlighted that only one in five patients in the UK derived positive benefits from antipsychotic medication and that approximately 1,800 patients in the UK at that time it was estimated died annually as a result of inappropriate antipsychotic prescribing. Since 2010, significant efforts have ben made to significantly reduce the number of prescriptions for antipsychotic drugs since 2010 with guidance issued to all GPs, pharmacists, and other healthcare professionals on how to provide care that meets the specific needs of each patient. Expert pharmacy teams have also been rolled out across the country to give advice to patients and maximise other treatment options, where appropriate. So it is hugely concerning to see such a significant rise in such a short period. I doubt that the presence of COVID-19 in the population is a suitable justification for this alteration in practice. I would agree with the research team who have said that said prescribing levels should be a “major focus” in the aftermath of the pandemic because of the risk of serious side effects to many current residents.
A further analysis found that care homes that had increased antipsychotic prescribing had significantly higher levels of overall neuropsychiatric symptoms and significantly higher levels of agitation compared with those which had lower prescribing rates. There were also 31% more staff sick days in the higher prescribing homes, more details about their findings can be found at https://alz.confex.com/alz/2022/meetingapp.cgi/Paper/67089
Clive Ballard, Professor of Age-related Diseases the University of Exeter College of Medicine and Health, commented:
“COVID-19 put tremendous pressure on care homes, and the majority of them must be applauded for maintaining relatively low antipsychotic prescribing levels amid incredibly difficult circumstances. However, there were very significant rises in antipsychotic prescribing in one third of care homes and we urgently need to find ways to prioritise support to prevent people with dementia being exposed to significant harms.”
Dr Richard Oakley, Associate Director of Research at the Alzheimer’s Society, said:
“This study shows the shocking and dangerous scale of the use of antipsychotic drugs to treat people with dementia in care homes. The Alzheimer’s Society has been campaigning for a move away from the model of ‘medicate first’, and funded research into alternatives to antipsychotic prescriptions, focused on putting people living with dementia at the centre of their own care. This drug-free, tailored care can help avoid the loss of lives associated with the harmful side effects of antipsychotic medications.”
So a message for Care Home staff and to the Regulators, let’s make an effort to reverse this ASAP, before more people are harmed.